Moderna Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 5,800

Employees

  • Stock Symbol
  • MRNA

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $24.71
  • (As of Thursday Closing)

Moderna General Information

Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Contact Information

Website
www.modernatx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 325 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 325 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Moderna Stock Performance

As of 17-Apr-2025, Moderna’s stock price is $24.71. Its current market cap is $9.6B with 387M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$24.71 $25.19 $23.15 - $170.47 $9.6B 387M 11.3M -$9.28

Moderna Financials Summary

As of 31-Dec-2024, Moderna has a trailing 12-month revenue of $3.2B.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 10,488,725 10,488,725 31,800,693 61,919,496
Revenue 3,199,000 3,199,000 6,754,000 18,875,000
EBITDA (3,819,000) (3,819,000) (3,704,000) 9,723,000
Net Income (3,561,000) (3,561,000) (4,714,000) 8,362,000
Total Assets 14,142,000 14,142,000 18,426,000 25,858,000
Total Debt 747,000 747,000 1,243,000 1,200,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Moderna Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Moderna‘s full profile, request access.

Request a free trial

Moderna Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Moderna‘s full profile, request access.

Request a free trial

Moderna Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The
Drug Discovery
Cambridge, MA
5,800 As of 2024

Cambridge, MA
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Moderna Competitors (43)

One of Moderna’s 43 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
BioCryst Pharmaceuticals Corporation Durham, NC
Arcturus Therapeutics Formerly VC-backed San Diego, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
CureVac Formerly VC-backed Tubingen, Germany
You’re viewing 5 of 43 competitors. Get the full list »

Moderna Patents

  • 176

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

Moderna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10272150-B2 Combination piv3/hmpv rna vaccines Active 22-Oct-2015
US-20180326045-A1 Combination piv3/hmpv rna vaccines Active 22-Oct-2015
US-20220152178-A1 Concatemeric peptide epitope rnas Inactive 30-Jul-2015
US-20190008938-A1 Concatemeric peptide epitope rnas Active 30-Jul-2015
US-12150980-B2 Concatemeric peptide epitope rnas Active 30-Jul-2015 A61K45/06
To view Moderna’s complete patent history, request access »

Moderna Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Moderna Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Moderna‘s full profile, request access.

Request a free trial

Moderna Investments & Acquisitions (5)

Moderna’s most recent deal was a PIPE with Generation Bio for . The deal was made on 23-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Generation Bio 23-Mar-2023 PIPE Biotechnology
OriCiro Genomics 04-Jan-2023 Merger/Acquisition Biotechnology
Valera 22-Oct-2015 Corporate Therapeutic Devices
Ribometrix 01-Jan-2015 Corporate Drug Discovery
Onkaido 14-Jan-2014 Corporate Drug Discovery
To view Moderna’s complete investments and acquisitions history, request access »

Moderna ESG

Risk Overview

Risk Rating

Updated November, 05, 2024

19.16 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Moderna’s complete esg history, request access »

Moderna Exits (2)

Moderna’s most recent exit was on 22-Oct-2015 from Valera. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Valera 22-Oct-2015 Completed
Onkaido 14-Jan-2014 Corporate Completed
To view Moderna’s complete exits history, request access »

Moderna Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Valera Cambridge, MA 2015
Onkaido Cambridge, MA 2014

Moderna FAQs

  • When was Moderna founded?

    Moderna was founded in 2010.

  • Where is Moderna headquartered?

    Moderna is headquartered in Cambridge, MA.

  • What is the size of Moderna?

    Moderna has 5,800 total employees.

  • What industry is Moderna in?

    Moderna’s primary industry is Drug Discovery.

  • Is Moderna a private or public company?

    Moderna is a Public company.

  • What is Moderna’s stock symbol?

    The ticker symbol for Moderna is MRNA.

  • What is the current stock price of Moderna?

    As of 17-Apr-2025 the stock price of Moderna is $24.71.

  • What is the current market cap of Moderna?

    The current market capitalization of Moderna is $9.6B.

  • What is Moderna’s current revenue?

    The trailing twelve month revenue for Moderna is $3.2B.

  • Who are Moderna’s competitors?

    Sarepta Therapeutics, BioCryst Pharmaceuticals, Arcturus Therapeutics, Alnylam Pharmaceuticals, and CureVac are some of the 43 competitors of Moderna.

  • What is Moderna’s annual earnings per share (EPS)?

    Moderna’s EPS for 12 months was -$9.28.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »